In 2024, we brought Optune Gio ® to more than 4,000 glioblastoma patients across the globe, earned FDA approval and launched Optune Lua ® in non-small cell lung cancer in the U.S., announced two ...

Learn more about whether Neogen Corporation or NovoCure Limited is a better investment based on AAII's A+ Investor grades, ...

CEO Ashley Cordova said: “In 2024, we brought Optune Gio to more than 4,000 glioblastoma patients across the globe, earned FDA approval and launched Optune Lua in non-small cell lung cancer in ...

Celgene aims to boost the effectiveness of its novel drug marizomib for aggressive brain tumour glioblastoma (GBM) by asking patients to wear a special cap. Marketed by Novocure, the Optune ...

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 ...